A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials

This was a phase II, open label, multicenter trial of an investigational protease inhibitor TMC114 in the presence of ritonavir (rtv) in HIV-1 infected participants who were randomized in trials TMC114-C201, TMC114-C207 or in sponsor selected phase I trials and who might derive benefit from TMC114 therapy, as judged by the investigator.

The trial consisted of a screening period of a maximum of 4 weeks, a 96-week treatment period and a 4-week follow-up period. The maximal trial duration for each participant was104 weeks. During the treatment period, all participants were receiving TMC114 in combination with RTV, orally, as 600/100 mg dose twice daily, in addition to an individually optimized background regimen of antiretroviral (ARV) therapy, selected by the investigator at a baseline of the study.

Sponsor provided a follow-up treatment with TMC114 for all participants who continued to benefit from treatment with TMC114/RTV until it became commercially available for the participant. Participants, who completed the 96 weeks of treatment period with TMC114, had the opportunity to roll over to the extension of this trial, if TMC114 was not locally commercially available.

Inclusion criteria

• Must be diagnosed with HIV
• Previously randomized in trials TMC114-C201, TMC114-C207 or in sponsor selected Phase I trials
• Agreed to take at least 2 antiretroviral agents from baseline onwards
• Could comply with the protocol requirements
• General medical condition, in the investigator's opinion, was not interfering with the assessments and the conduct of the trial

Exclusion criteria

• A disallowed concomitant therapy
• Current or past history of active alcohol and/or drug use
• Pregnant or breast-feeding females
• Any active or unstable medical condition (e.g., tuberculosis; cardiac dysfunction; pancreatitis; acute viral infections)
• Clinical or laboratory evidence of active liver disease, liver impairment/dysfunction or cirrhosis
• Clinically significant allergy or hypersensitivity to any of the excipients of the investigational medication
• Laboratory abnormalities at screening (criteria variable according to the test)